KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Goodwill (2016 - 2022)

Nektar Therapeutics has reported Goodwill over the past 13 years, most recently at $76.5 million for Q4 2022.

  • Quarterly results put Goodwill at $76.5 million for Q4 2022, changed 0.0% from a year ago — trailing twelve months through Dec 2022 was $76.5 million (changed 0.0% YoY), and the annual figure for FY2022 was $76.5 million, changed 0.0%.
  • Goodwill for Q4 2022 was $76.5 million at Nektar Therapeutics, roughly flat from $76.5 million in the prior quarter.
  • Over the last five years, Goodwill for NKTR hit a ceiling of $76.5 million in Q1 2018 and a floor of $76.5 million in Q1 2018.
  • Median Goodwill over the past 5 years was $76.5 million (2018), compared with a mean of $76.5 million.
  • Peak annual rise in Goodwill hit 0.0% in 2018, while the deepest fall reached 0.0% in 2018.
  • Nektar Therapeutics' Goodwill stood at $76.5 million in 2018, then changed by 0.0% to $76.5 million in 2019, then changed by 0.0% to $76.5 million in 2020, then changed by 0.0% to $76.5 million in 2021, then changed by 0.0% to $76.5 million in 2022.
  • The last three reported values for Goodwill were $76.5 million (Q4 2022), $76.5 million (Q3 2022), and $76.5 million (Q2 2022) per Business Quant data.